Osteoarthritis

Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials

Osteoarthritis CartilagePublished Systematic review and meta-analysis of randomised trials

Pooled result · Pain relief (10 cm VAS)Result — go to the resultWeighted mean difference −0.74 cm 95% CI −1.16 to −0.33

Authors' conclusion

Intra-articular injection of MSCs for chronic knee pain associated with OA probably provides little to no improvement in pain or physical function.

Study context

Population
Patients with chronic pain associated with knee osteoarthritis (OA)
Participants
807 patients16 trials
Comparison
MSC therapy vs placebo or usual care
Outcome
Pain relief (10 cm VAS)
Follow-up
3-6 months
Methodological detailsrandom-effects meta-analysis, GRADE certainty of evidence
  • Random-effects meta-analysis
  • GRADE certainty of evidence

Pooled result

As reported in the abstract

Weighted mean difference

−0.74 cm

95% CI −1.16 to −0.33

MSC therapyvs Placebo or usual care
weighted mean difference −0.74 cm (95% CI −1.16 to −0.33)

Further pooled results

OutcomeWeighted mean difference (points) (95% CI)
Physical functioning (SF-36 physical functioning subscale, 100-point) · 3-6 monthsMID 10-points; moderate certainty2.23 (−0.97 to 5.43)
Physical functioning (SF-36 PF subscale, 100-point) · 12 monthsLow certainty19.36 (−0.19 to 38.9)
OutcomeWeighted mean difference (cm) (95% CI)
Pain (10 cm VAS) · 12 monthsModerate certainty−0.73 (−1.69 to 0.24)

Safety

OutcomeRR (95% CI)
Any adverse eventsLow certainty2.67 (1.19–5.99)
Pain and swelling of the knee jointLow certainty1.58 (1.04–2.38)

Original publication

Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials. Osteoarthritis Cartilage. Published 20 May 2024. doi:10.1016/j.joca.2024.04.021

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.